tenofovir disoproxil fumarate 300 MG Oral Tablet [Viread]
tenofovir disoproxil fumarate
RxCUI: 352050
What the CMS Formulary Data Shows for tenofovir disoproxil fumarate 300 MG Oral Tablet [Viread]
Per the CMS 2026 Part D formulary file, tenofovir disoproxil fumarate 300 MG Oral Tablet [Viread] (RxNorm concept RXCUI 352050, generic name tenofovir disoproxil fumarate) appears on 1 distinct formulary file spanning 2 Medicare Part D plan offerings - 0% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 1, with a cross-plan average of Tier 1.
Real-world access to tenofovir disoproxil fumarate 300 MG Oral Tablet [Viread] depends on utilization management as much as tier placement: 0% of covering formularies require prior authorization. 0% require step therapy. 100% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 15,480 Part D beneficiaries filled tenofovir disoproxil fumarate 300 MG Oral Tablet [Viread] in 2023, with total plan-and-beneficiary spending of $19,689,252 and an average per-beneficiary annual cost of $1,271.92. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry tenofovir disoproxil fumarate 300 MG Oral Tablet [Viread] today.
Coverage Details
- Formularies covering
- 1
- Plans covering
- 2
- Coverage rate
- 0%
- Tier range
- Tier 1, Preferred Generic
- Average tier
- Tier 1, Preferred Generic
Restrictions
- Prior authorization required
- 0% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 100% of formularies
2023 Medicare Spending
- Beneficiaries
- 15,480
- Total spending
- $19,689,252
- Avg per beneficiary
- $1,271.92
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering tenofovir disoproxil fumarate 300 MG Oral Tablet [Viread]
2 Medicare Advantage plans with Part D drug coverage include this drug.
| Plan | Insurer | Tier | PA | Premium | States |
|---|---|---|---|---|---|
| Hamaspik Medicare Choice (HMO D-SNP) | HAMASPIK, INC. | T1 | No | $0 | NY |
| Hamaspik Medicare Select (HMO D-SNP) | HAMASPIK, INC. | T1 | No | $34.50 | NY |
Frequently Asked Questions
Is tenofovir disoproxil fumarate 300 MG Oral Tablet [Viread] covered by Medicare Part D?
Yes, tenofovir disoproxil fumarate 300 MG Oral Tablet [Viread] is covered by 2 Medicare Part D plans (0% of all Part D formularies).
What tier is tenofovir disoproxil fumarate 300 MG Oral Tablet [Viread] on Medicare Part D plans?
tenofovir disoproxil fumarate 300 MG Oral Tablet [Viread] averages Tier 1 across Part D plans, ranging from Tier 1 to Tier 1.
Does tenofovir disoproxil fumarate 300 MG Oral Tablet [Viread] require prior authorization?
0% of Part D formularies require prior authorization for tenofovir disoproxil fumarate 300 MG Oral Tablet [Viread]. Step therapy: 0%. Quantity limits: 100%.
How much does Medicare spend on tenofovir disoproxil fumarate 300 MG Oral Tablet [Viread]?
In 2023, total Medicare Part D spending on tenofovir disoproxil fumarate 300 MG Oral Tablet [Viread] was $19,689,252, covering 15,480 beneficiaries. The average spend per beneficiary was $1,271.92.
Read our methodology - how this data is sourced, computed, and verified.